Business
M&A Solutions/DD
Providing full-life cycle solutions for MAH project
M&A Solutions/DD
With the deepening of
China's institutional reform of pharmaceutical enterprises and the adjustment
of industrial structure, many pharmaceutical enterprises have begun to pay
attention to the construction of a complete industrial chain to enhance their core
competitiveness, pursue high-quality development strategies, and to achieve a large-scale,
intensive, and international business objective via Merger and Acquisition
(M&A).
In the past years, Canny has supported for many "M&A Risk Avoidance and Compliance Solutions" project for MNC and local companies to assist for regulatory compliance assessment and risks avoidance during the M&A process by sending our experts to support for Due Diligence for the aspect of regulatory Affairs compliance and GMP compliance.
CANNY-Your Trustworthy Consultant for Drug Regulatory Compliance!
-
27 years
of professional consulting experience in the pharmaceutical industry -
930 +
GMP certification projects for China, EU, FDA, UK, Japan, Australia and WHO inspection -
370 +
Validation execution and guidance projects -
2800 +
Globally RA registration projects -
1580 +
Globally clients and pharmaceutical partners -
30 +
Experts from China, US and EU
Professional Services, Standardized SOPs
Providing full-life cycle solutions for MAH project
If you have business needs
Contact Us
